Lung Cancer Therapeutics Market by Molecules (Biologics, Small Molecules), Disease (NSCLC, SCLC), Cancer Type, Therapy, Distribution - Global Forecast 2024-2030

Lung Cancer Therapeutics Market by Molecules (Biologics, Small Molecules), Disease (NSCLC, SCLC), Cancer Type, Therapy, Distribution - Global Forecast 2024-2030


The Lung Cancer Therapeutics Market size was estimated at USD 25.04 billion in 2023 and expected to reach USD 27.12 billion in 2024, at a CAGR 8.39% to reach USD 44.03 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lung Cancer Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lung Cancer Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Molecules

Biologics

Small Molecules
Disease

NSCLC

SCLC
Cancer Type

Lung Carcinoid Tumor

Non-small Cell Lung Cancer

Small Cell Lung Cancer
Therapy

Chemotherapy

Immunotherapy
Atezolizumab
Durvalumab
Nivolumab
Pembrolizumab

Radiation Therapy
External Beam
Internal Beam
Systemic

Targeted Therapy
Bevacizumab
Dabrafenib/Trametinib
Erlotinib Hydrochloride
Osimertinib
Distribution

Hospital Pharmacies

Online Phramacies

Retail Pharmacies
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Lung Cancer Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lung Cancer Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Lung Cancer Therapeutics Market?
4. What is the market share of the leading vendors in the Lung Cancer Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Lung Cancer Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Lung Cancer Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in prevalence of lung cancer across the globe
5.1.1.2. Growing awareness regarding enhanced health care
5.1.1.3. Rising government initiatives for lung cancer treatment
5.1.2. Restraints
5.1.2.1. Huge availability of the generic drugs
5.1.2.2. Reduced life expectancy of patients undertaking lung cancer treatment
5.1.3. Opportunities
5.1.3.1. Increasing funding in the field of research and development of new treatment
5.1.3.2. Adoption of advanced therapy such as immunotherapy
5.1.4. Challenges
5.1.4.1. Risk of side effects of radiation and chemotherapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Lung Cancer Therapeutics Market, by Molecules
6.1. Introduction
6.2. Biologics
6.3. Small Molecules
7. Lung Cancer Therapeutics Market, by Disease
7.1. Introduction
7.2. NSCLC
7.3. SCLC
8. Lung Cancer Therapeutics Market, by Cancer Type
8.1. Introduction
8.2. Lung Carcinoid Tumor
8.3. Non-small Cell Lung Cancer
8.4. Small Cell Lung Cancer
9. Lung Cancer Therapeutics Market, by Therapy
9.1. Introduction
9.2. Chemotherapy
9.3. Immunotherapy
9.4.1. Atezolizumab
9.4.2. Durvalumab
9.4.3. Nivolumab
9.4.4. Pembrolizumab
9.4. Radiation Therapy
9.5.1. External Beam
9.5.2. Internal Beam
9.5.3. Systemic
9.5. Targeted Therapy
9.6.1. Bevacizumab
9.6.2. Dabrafenib/Trametinib
9.6.3. Erlotinib Hydrochloride
9.6.4. Osimertinib
10. Lung Cancer Therapeutics Market, by Distribution
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Phramacies
10.4. Retail Pharmacies
11. Americas Lung Cancer Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Lung Cancer Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Lung Cancer Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AbbVie Inc.
15.1.2. Astellas Pharma Inc.
15.1.3. AstraZeneca PLC
15.1.4. Boehringer Ingelheim GmbH
15.1.5. Bristol Myers Squibb Company
15.1.6. Celgene Corporation
15.1.7. Eli Lilly and Company
15.1.8. F. Hoffmann-La Roche AG
15.1.9. Genentech, Inc.
15.1.10. GlaxoSmithKline PLC
15.1.11. Merck KGaA
15.1.12. Novartis AG
15.1.13. Pfizer Inc.
15.1.14. Sanofi S.A.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. LUNG CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LUNG CANCER THERAPEUTICS MARKET DYNAMICS
FIGURE 7. LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2030 (%)
FIGURE 8. LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 10. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 12. LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
FIGURE 14. LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 16. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings